KRAS and adenomyosis: These results suggest that epigenetic silencing may contribute to the PR downregulation observed in KRAS-mutated adenomyosis, and that DNG may be less effective in treating KRAS-mutated adenomyosis due to this suppression of PR-A/B expression.